Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors

NCT04933669 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

122

Enrollment

OTHER

Sponsor class

Conditions

Progression-free Survival
Gastrointestinal Stromal Tumor
Neoadjuvant

Interventions

DRUG: Imatinib

Sponsor

First Affiliated Hospital of Zhejiang University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]